Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioStem Technologies, Inc. (OTC: BSEM).

Full DD Report for BSEM

You must become a subscriber to view this report.


Recent News from (OTC: BSEM)

BioStem Technologies Inc. Enters Into Consulting and Advisory Agreement with Dr. Irmgard Huber
Pompano Beach, FL, April 04, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, today annou...
Source: GlobeNewswire
Date: April, 04 2018 10:28
BioStem Technologies, Inc. Announces Letter of Intent with CCM Pharma Solutions to Co-Develop Multiple Solid to Liquid Dose Drugs Through 505(b)(2) Accelerated FDA Approval Process
Pompano Beach, FL, March 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, today announ...
Source: GlobeNewswire
Date: March, 26 2018 19:22
BioStem Technologies Inc. Announces Engagement of Dr. Felix Amon for Pharmaceutical Business Development
Pompano Beach, FL, March 13, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced t...
Source: GlobeNewswire
Date: March, 13 2018 18:15
BioStem Technologies Inc. Enter into Agreement with Barbara Krutchkoff, PhD. To Guide Scientific Affairs
Pompano Beach, FL, March 09, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, has...
Source: GlobeNewswire
Date: March, 09 2018 17:09
BioStem Technologies intents to acquire GIINT
BioStem Technologies ( OTCPK:BSEM ) signed Letter of Intent to acquire Grupo Impulso De Incentivacion Para Nuevas Tecnologías (“GIINT”). More news on: BioStem Technologies, Inc., Merger & acquisition news, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 27 2018 05:56
BioStem Technologies Inc. Announces Intent to Acquire GIINT
Pompano Beach, FL, Feb. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenera...
Source: GlobeNewswire
Date: February, 26 2018 20:27
BioStem Technologies Inc. Applies for Uplisting to the OTCQX Market
Pompano Beach, FL, Feb. 16, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine,...
Source: GlobeNewswire
Date: February, 16 2018 09:44
BioStem Technologies Inc. Announces New Transfer Agent, V Stock Transfer
Pompano Beach, FL, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Pompano Beach, FL (GLOBE NEWSWIRE) – BioStem Technologies, Inc. (OTC PINK: BSEM) (the “Company”) announced today that it has changed the transfer agent and registrar of its common stock to V Stock Transfer, based...
Source: GlobeNewswire
Date: February, 09 2018 10:39
BioStem Technologies Adds Chief Revenue Officer to Executive Team
Pompano Beach, FL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) – BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals ...
Source: GlobeNewswire
Date: February, 08 2018 17:00
BioStem Technologies, Inc. Announces the Engagement of Investment Banking Firm Young America Capital for 15 Million Dollar 506(c) Offering.
Pompano Beach, FL, Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”) announced today the engagement of investment banking firm Young America Capital as an advisor for the Company’s upcoming 15 Million dolla...
Source: GlobeNewswire
Date: January, 26 2018 09:45

 


About BioStem Technologies, Inc. (OTC: BSEM)

Logo for BioStem Technologies, Inc. (OTC: BSEM)

BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drives shareholder value.

 

 

 

Current Management

  • Henry VanVurst / CEO, CoFounder
  • Andrew VanVurst / COO, CoFounder
  • Jason Matuszewski / CFO, President, CoFounder
  • Larry Jones / Chief Revenue Officer
  • Henry VanVurst / Chairman
  • Jason Matuszewski /
  • Dr. Jennie Sandqvist / Independent Director
  • Andrew VanVurst /
  • Robert Watson / Independent Director

Current Share Structure

  • Market Cap: $62,681,124 - 03/15/2018
  • Authorized: 975,000,000 - 02/15/2018
  • Issue and Outstanding: 7,439,013 - 01/31/2018
  • Float: 4,214,289 - 02/15/2018

 


Recent Filings from (OTC: BSEM)

Quarterly Report - Quarterly Disclosure Statement Q3 - 2017
Filing Type: Quarterly Report - Quarterly Disclosure Statement Q3 - 2017Filing Source: OTC Markets
Filing Date: November, 17 2017
Quarterly Report - Quarterly Financial Footnotes Q3 - 2017
Filing Type: Quarterly Report - Quarterly Financial Footnotes Q3 - 2017Filing Source: OTC Markets
Filing Date: November, 16 2017
Quarterly Report - Quarterly Financials Q3 2017
Filing Type: Quarterly Report - Quarterly Financials Q3 2017Filing Source: OTC Markets
Filing Date: November, 16 2017
Quarterly Report - Quarterly Disclosure Statement
Filing Type: Quarterly Report - Quarterly Disclosure StatementFiling Source: OTC Markets
Filing Date: August, 28 2017
Quarterly Report - Quarterly Financial Footnotes
Filing Type: Quarterly Report - Quarterly Financial FootnotesFiling Source: OTC Markets
Filing Date: August, 28 2017
Quarterly Report - Quarterly Financials
Filing Type: Quarterly Report - Quarterly FinancialsFiling Source: OTC Markets
Filing Date: August, 28 2017
Notification of Late Filing - BioStem Technologies Announces Delay in filing Q2 Financials
Filing Type: Notification of Late Filing - BioStem Technologies Announces Delay in filing Q2 FinancialsFiling Source: OTC Markets
Filing Date: August, 15 2017
Quarterly Report - Quarterly Financial Footnotes
Filing Type: Quarterly Report - Quarterly Financial FootnotesFiling Source: OTC Markets
Filing Date: May, 19 2017
Quarterly Report - Quarterly Financials
Filing Type: Quarterly Report - Quarterly FinancialsFiling Source: OTC Markets
Filing Date: May, 19 2017
Notification of Late Filing - BioStem Technologies Announces Delay in filing Q1 Financials
Filing Type: Notification of Late Filing - BioStem Technologies Announces Delay in filing Q1 FinancialsFiling Source: OTC Markets
Filing Date: May, 15 2017

 

 


Daily Technical Chart for (OTC: BSEM)

Daily Technical Chart for (OTC: BSEM)


Stay tuned for daily updates and more on (OTC: BSEM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BSEM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BSEM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BSEM and does not buy, sell, or trade any shares of BSEM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/